{"id":38893,"date":"2025-08-08T16:53:15","date_gmt":"2025-08-08T08:53:15","guid":{"rendered":"https:\/\/flcube.com\/?p=38893"},"modified":"2025-08-08T16:53:16","modified_gmt":"2025-08-08T08:53:16","slug":"jingxin-pharma-signs-patent-license-for-cariprazine-hydrochloride-with-gedeon-richter","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38893","title":{"rendered":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter"},"content":{"rendered":"\n<p>China-based Jingxin Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/002020:SHE\">SHE: 002020<\/a>) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.<\/p>\n\n\n\n<p><strong>Drug Profile<\/strong><br>Cariprazine hydrochloride is an atypical antipsychotic drug that acts as a partial agonist of dopamine D2 and D3 receptors. It is primarily used for the treatment of adult schizophrenia, the acute treatment of manic or mixed episodes associated with bipolar I disorder, and as an adjunctive treatment for major depressive disorder (MDD). The drug has received regulatory approvals from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for various indications, including schizophrenia and bipolar disorder.<\/p>\n\n\n\n<p><strong>Market Potential<\/strong><br>Despite its widespread approval and use in other markets, cariprazine hydrochloride has not yet been approved in China. Jingxin Pharmaceutical has officially submitted a marketing application to China&#8217;s National Medical Products Administration (NMPA) to bring this innovative treatment option to Chinese patients.<\/p>\n\n\n\n<p><strong>Agreement Details<\/strong><br>Upon fulfilling certain conditions, including regulatory approval, Jingxin Pharmaceutical will pay Gedeon Richter milestone payments totaling up to 530,000 euros. Additionally, after the market launch of cariprazine hydrochloride products in mainland China, Jingxin will pay sales royalties based on net sales.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u4eac\u65b0\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0eGedeon-Richter-Plc.\u7b7e\u7f72\u4e13\u5229\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4eac\u65b0\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0eGedeon Richter Plc.\u7b7e\u7f72\u4e13\u5229\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-afb9d9f4-1084-4307-960c-98c0d2e5b064\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u4eac\u65b0\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0eGedeon-Richter-Plc.\u7b7e\u7f72\u4e13\u5229\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\">\u4eac\u65b0\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0eGedeon Richter Plc.\u7b7e\u7f72\u4e13\u5229\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u4eac\u65b0\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0eGedeon-Richter-Plc.\u7b7e\u7f72\u4e13\u5229\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-afb9d9f4-1084-4307-960c-98c0d2e5b064\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[30,1598,1826],"class_list":["post-38893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-biotech","tag-gedeon-richter","tag-jingxin-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38893\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter\" \/>\n<meta property=\"og:description\" content=\"China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38893\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-08T08:53:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T08:53:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter\",\"datePublished\":\"2025-08-08T08:53:15+00:00\",\"dateModified\":\"2025-08-08T08:53:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0801-1.webp\",\"keywords\":[\"Biotech\",\"Gedeon Richter\",\"Jingxin Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38893#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38893\",\"name\":\"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0801-1.webp\",\"datePublished\":\"2025-08-08T08:53:15+00:00\",\"dateModified\":\"2025-08-08T08:53:16+00:00\",\"description\":\"China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38893\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0801-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0801-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38893#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38893","og_locale":"en_US","og_type":"article","og_title":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter","og_description":"China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.","og_url":"https:\/\/flcube.com\/?p=38893","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-08T08:53:15+00:00","article_modified_time":"2025-08-08T08:53:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38893#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38893"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter","datePublished":"2025-08-08T08:53:15+00:00","dateModified":"2025-08-08T08:53:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38893"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38893#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp","keywords":["Biotech","Gedeon Richter","Jingxin Pharmaceutical"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38893#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38893","url":"https:\/\/flcube.com\/?p=38893","name":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38893#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38893#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp","datePublished":"2025-08-08T08:53:15+00:00","dateModified":"2025-08-08T08:53:16+00:00","description":"China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License Agreement with Gedeon Richter Plc. Under the agreement, Gedeon Richter will grant Jingxin Pharmaceutical an exclusive patent license to develop, manufacture, and commercialize cariprazine hydrochloride formulations and active pharmaceutical ingredients (API) within mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38893#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38893"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38893#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp","width":1080,"height":608,"caption":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38893#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0801-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38893"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38893\/revisions"}],"predecessor-version":[{"id":38896,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38893\/revisions\/38896"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38895"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}